Effect of thiabendazole on 17β-estradiol-induced mammary tumor in rats

• Main Authors: Chao-Yun Yuan, 袁朝云
• Other Authors: Ho Lin
• Format: Others
• Language: zh-TW
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/uzsmcy

碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 101 === The diseases are increasing with industrialization especially in cancer, which is one of top ten. Breast cancer is one of the most serious diseases with number one in incidence and number four in death rate. Due to the westernized food and change of live style the incidence of breast cancer is increasing with year. It is quite important for us to develop new drugs for breast cancer. Our previous study showed that pregnant rat was orally administered in utero exposure with stain Rhodamine B resulted in severe embryo lethality. Previous report showed that Rhodamine B increased the aromatase activity, which transfer testosterone into estradiol. Based on the aromatase antagonistic activity by thiabendazole our laboratory conduct a study to investigate the effect of co-treatment with thiabendazole and Rhodamine B on embryo lethality in rats. Results showed that thiabendazole completely relieved the embryo lethality in rats. Based on the hypothesis this study aim to investigate if the thiabendazole antagonize the estradiol-induced mammary tumors in rats. Wistar rats were implanted with 5, 10 and 15 mg 17β-estradiol/pellet/rat, 50, 100 and 200 mg/pellet/rat thiabendazole, 5, 10 and 15 mg 17β-estradiol/pellet/rat each and 50, 100 and 200 mg/pellet/rat thiabendazole. Wistar rats, 10 week old, were implanted for 10 months. Results showed that body weight were increased with treatment period. The incidence of breast tumor with gross and pathology were as follows. Positive control 17β-estradiol induced breast tumor with dose response while thiabendazole did not. Though the result is not statistically significant, co-treatment with 10 and 15 mg 17β-estradiol/pellet/rat and 50, 100 and 200 mg/pellet/rat thiabendazole decreased the incidence of breast cancer when compared with 17β-estradiol alone. Immunohistochemistry data showed that 17β-estradiol induced ERα activity but not in ERβ and aromatase. Co-treatment with 17β-estradiol each and various thiabendazole significantly decreased the ERα activity with dose response. We concluded that the thiabendazole antagonistic effect on the 17β-estradiol induced breast cancer and the result is near the significant level statistically. Owing to the unclear underlying mechanism of breast cancer and the role of aromatase in caner induction it is need to be done for the prevention.